Dr. Lin joins Nuvig to advance NVG-2089 through Phase 2 studies in chronic inflammatory demyelinating polyneuropathy and immune thrombocytopenia and shape the next wave of immunomodulating therapies from the company’s BESTech™ platform Palo Alto, Calif., Nuvig Therapeutics, Inc., (“Nuvig”) a privately held biotechnology company developing novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases, today…
